NRC
BXRX

North Run Capital’s Baudax Bio, Inc. Common Stock BXRX Stock Holding History

North Run Capital’s Portfolio BXRX Stock Details BXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-722
Closed -$2.8M – 19
2020
Q3 		$2.8M Sell
722
-102
-12% -$462K 3.23% 14
2020
Q2 		$4.78M Hold
824
– – 6.56% 8
2020
Q1 		$2.86M Buy
824
+639
+345% +$6.03M 2.87% 15
2019
Q4 		$1.79M Buy
+185
New +$1.58M 1.41% 18

Other funds holding BXRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

North Run Capital's BXRX Position: Q4 2020 in Review

North Run Capital sold out of Baudax Bio, Inc. Common Stock (BXRX) in Q4 2020, closing a stake of 722 shares — an estimated $2.8M sold.

North Run Capital first reported a position in BXRX in Q4 2019 and held it in 4 quarters. The position peaked at $4.78M in Q2 2020. 34 funds tracked by Wall St. Rank hold BXRX as of Q4 2020.

  • North Run Capital reported no remaining Baudax Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • North Run Capital sold 722 Baudax Bio, Inc. Common Stock shares in Q4 2020, an estimated $2.8M.
  • North Run Capital first reported a position in Baudax Bio, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • North Run Capital's Baudax Bio, Inc. Common Stock position peaked at $4.78M in Q2 2020.
  • 34 funds tracked by Wall St. Rank held Baudax Bio, Inc. Common Stock as of Q4 2020.

Based on North Run Capital's 13F filing for Q4 2020, filed 16 Feb 2021.